Full-Time
Product Quality Engineer
Revvity
1,001-5,000 employees
No salary listed
Cardiff, UK
In Person
Be able to travel within UK and overseas as required.
 QA & Testing (1) |
|---|
- Applied knowledge of the requirements of ISO 13485 and ISO 9001.
- Ideally qualified to minimum Higher National Diploma level (or equivalent) in an appropriate scientific subject with a minimum of 3 to 5 years related professional experience within Quality working to ISO 13485 and ISO 9001.
- Strong focus on Continuous Improvement, with demonstrated proven track record of leading problem solving and root cause analysis teams (Six Sigma or Quality Tools approach).
- Strong Design Control understanding from concept to launch and a proven track record as quality lead developing and transferring new products to manufacturing.
- Must be customer focused with passion, energy and drive to continuously improve the way we do business.
- Must be able to persuade, convince and influence others and develop structured arguments.
- Must be able to work independently and have a proactive approach.
- Must be capable of working under pressure and have ability to get things done.
- Be able to travel both within UK and Overseas as required.
- To take ownership for the quality of products within Manufacturing Operations according to ISO 9001 and ISO 13485.
- Lead / Drive Customer Complaints from cradle to grave.
- Lead and/or participate to specific production yield, productivity and customer focused improvement projects.
- Support new product development activities from concept through launch including guidance to the NPD team as it relates to ISO 9001 and ISO 13485.
- Lead and Provide guidance in conducting structured root cause investigations in manufacturing and at supplier facilities.
- Support/lead DFMEA and PFMEA activities.
- Process analysis and improvement through utilization of risk management, statistical tools and six sigma methodologies.
- Support and where applicable conduct internal and external audits as well as quality performance analysis and reporting.
- Work with Operations, Purchasing and Supplier Quality Engineering to improve product quality and reduce cost through the utilization of root cause investigation tools such as 5 WHY’s, fishbone diagrams, cause and effect matrix.
- Provide input into the project Design Inputs, Product Specification Development, and applicable design control documents as defined per Revvity’s product development process.
- Plan and manage product quality during transfer to production, including design and process validation.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
2023
Simplify's Take
What believers are saying
- China immunodiagnostics divestiture boosts 2026 organic growth 100bps to 3-4% and margins 30bps.
- Q1 2026 delivered 3% organic growth, $1.06 EPS beating $1.02-$1.04 guidance amid pharma recovery.
- SLAS2026 launches like EnVision Nexus One and AssayMate accelerate high-throughput drug discovery workflows.
What critics are saying
- Quest Diagnostics and Labcorp undercut ChLIA tests with cheaper saliva assays, eroding share in 12-18 months.
- China divestiture fails by end-2027 due to regulatory delays, dragging 6% revenue amid policy headwinds.
- Q2 software revenue drops 20%, accelerating as Benchling captures AI-driven pharma spending in H2 2026.
What makes Revvity unique
- FDA-cleared ChLIA assays enable direct total and free testosterone measurement on single automated platform.
- Opera Phenix OptIQ achieves 95% camera efficiency for 3D organoid screening with Phenologic.AI.
- Signals BioDesign cloud platform supports 1,000-construct cloning integrated with Signals One.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Revvity who can refer or advise you
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Company Match
Employee Stock Purchase Plan
Company News
Revvity has launched Signals BioDesign, a cloud-native molecular cloning solution designed to streamline biologics research workflows for biotech and pharmaceutical R&D teams. The platform supports core cloning methodologies including Golden Gate, Gibson assembly, restriction/ligation, primer design and Sanger sequencing analysis. The solution enables high-throughput combinatorial cloning for up to 1,000 constructs whilst maintaining workflow simplicity. As the only cloud-native molecular cloning tool integrated with the Signals One platform, it connects design with existing bioregistration and experiment capture in a unified ecosystem. The cloud architecture provides real-time team collaboration, centralised bio-sequence libraries and granular access controls. Revvity will introduce Signals BioDesign at the Bio-IT World Conference & Expo in Boston from 19–21 May.
Revvity Omni - now available from John Morris Group. New Brand Announcement John Morris Group appointed distributor for Revvity Omni in Australia and New Zealand. John Morris Group | New Distribution Partnership | Australia & New Zealand John Morris Group is pleased to announce its appointment as an authorised distributor for the Revvity Omni range of homogenisers and sample preparation solutions across Australia and New Zealand. Supported applications. Revvity Omni is internationally respected for its expertise in sample disruption and homogenisation, with proven solutions supporting a broad range of industries and disciplines: Molecular Biology & Genomics Food & Agricultural Testing Environmental Analysis Pharmaceuticals & Biotechnology Clinical Research Product range. The Revvity Omni range, now available to order through John Morris Group, includes: Bead Mill Homogenisers, Manual and Programmable Fast, reliable bead-beating technology for consistent, reproducible sample disruption across biological, environmental, and food matrices. Models include the Bead Ruptor 4, 12, 24, Elite, and 96+, covering sample volumes from 0.5 mL to 50 mL. Rotor-Stator Homogenisers High-shear homogenisers for rapid disruption of tissue, cells, and tough sample types. The range includes the Tissue Homogenizer (TH220), Tissue Master (TM125), Macro ES, Mixer, and General Lab Homogenizer 850, with a broad selection of probe sizes and chamber accessories for small to large volumes. Automated Homogenisation Systems with Integrated Liquid Handling Streamline high-throughput sample preparation with automation and precision liquid handling in a single integrated platform. Ideal for laboratories processing large sample volumes requiring consistent, walk-away results. Tubes, Bead Kits & Consumables A comprehensive range of prefilled bead kits (0.1 mm to 6.5 mm in glass, ceramic, garnet and stainless steel), bulk bead media, sample tubes (0.5 mL to 50 mL), 96-well deep well plates, and Omni Tips, all optimised for use with the Revvity Omni instrument range. Local support across Australia & New Zealand. Through this distribution arrangement, customers will benefit from the full John Morris Group service offering: Local Technical Support Application Guidance Product Demonstrations Quotations After-Sales Service John Morris Group has a long history of supporting scientific and research customers with high-quality instrumentation and responsive local service. The addition of the Revvity Omni range further strengthens the company's offering in sample preparation and workflow automation. About Revvity Omni Revvity Omni delivers globally recognised expertise in sample disruption and homogenisation, trusted by laboratories worldwide for performance, reliability, and innovation in sample preparation. About John Morris Group Founded in 1952, John Morris Group has been a trusted supplier of scientific, environmental, and industrial instrumentation in Australia and New Zealand for over 70 years, with offices nationwide and a large team of qualified service engineers. This new partnership expands John Morris Group's laboratory portfolio and strengthens local access to Omni's globally recognised sample preparation technologies, spanning bead mill and rotor-stator homogenisation and automated liquid handling workflows. Customers across Australia and New Zealand can now engage directly with John Morris Group for product selection, quotations, demonstrations, and ongoing local support. Interested in Revvity Omni? Speak with its team for product selection support, a demonstration, or a quote. John Morris Group is ready to help you find the right solution for your laboratory. John Morris Group. Australia & New Zealand's trusted partner for scientific instruments, laboratory equipment, and technical solutions since 1962. March 6, 2026
Revvity unveils new high-impact discovery platforms and showcases recent innovations at SLAS2026. Revvity, Inc. announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are the Opera Phenix OptIQ(TM) high-content screening system, the EnVision Nexus(TM) One multimode plate reader, and the AssayMate(TM) workstation, alongside other recently introduced solutions spanning sample preparation, screening, advanced imaging, and lab automation. At booth #612, Revvity will showcase an expanded portfolio of integrated workflow solutions designed to support discovery programs from early screening through data-driven decision making. Solutions debuting at SLAS2026 include: * Opera Phenix OptIQ high-content screening system: Designed to reduce bottlenecks in phenotypic screening and advanced cellular analysis, this system enables quantitative imaging across complex biological models, including 3D organoids and organ-on-chip systems. Peak camera quantum efficiency has increased from 60 % to 95 %, improving image sensitivity and data quality, and the system is equipped with Phenologic.AI image analysis software that now includes new classification capabilities, such as cell cycle analysis, expanding beyond its previous focus on segmentation. Laser-based autofocus has been enhanced to better support multi-layer sample carriers, and a new Harmony(TM) software building block enables detection of organoids in brightfield image stacks. * EnVision Nexus One multimode plate reader: The newest addition to the EnVision Nexus family, the EnVision Nexus One delivers the trusted sensitivity and reliability of the Envision Nexus platform in a streamlined single-detector configuration optimized for high-throughput screening environments. Designed to simplify automation and integration while supporting evolving assay needs, the system provides enhanced sensitivity across TRF, Alpha, and luminescence detection. The EnVision Nexus One is powered by intuitive Kaleido(TM) software with 21 CFR Part 11 compliance tools and offers flexible configuration options to support a wide range of laboratory workflows. * AssayMate workstation: The compact, benchtop AssayMate liquid handler delivers intelligent automation performance for labs of any size. It supports a wide volume range of 3-1000 μL without requiring head changes, using a fixed 8-channel head and gripper configuration. Intelligent features such as pressure-based liquid level detection (PLLD) and built-in workflow error handling - including detection of missing plate lids - enable reliable operation and quick experiment resumption. A reconfigurable recessed deck accommodates optional modules such as heater shakers, heater coolers, and magnetic blocks, while AssayPREP(TM) software provides a user-friendly, drag-and-drop interface that requires minimal training. SLAS2026 marks a key milestone for Revvity with the introduction of new platforms that support the evolving needs of discovery labs, These launches integrate automation, trusted assay technologies, and AI-driven imaging to help customers accelerate results while maintaining data quality." Kevin Quick, Vice President, Platforms, Revvity
Revvity has launched multiple discovery platforms at SLAS2026 in Boston, designed to accelerate high-throughput drug discovery workflows. The new products include the Opera Phenix OptIQ high-content screening system, EnVision Nexus One multimode plate reader, and AssayMate workstation. The Opera Phenix OptIQ features improved camera quantum efficiency from 60% to 95% and enhanced Phenologic.AI image analysis software with new classification capabilities. The EnVision Nexus One offers a streamlined single-detector configuration optimised for high-throughput screening. The compact AssayMate workstation delivers intelligent automation with a volume range of 3–1000 µL without requiring head changes. Revvity, which reported 2025 revenue of $2.9 billion, serves pharmaceutical, biotech, and diagnostic lab customers across more than 160 countries.
Revvity reported fourth quarter 2025 revenue of $772 million, up 6% with 4% organic growth, and adjusted earnings per share from continuing operations of $1.70, compared to $1.42 a year earlier. GAAP EPS was $0.87, up from $0.78. For full year 2025, revenue reached $2.86 billion, up from $2.76 billion in 2024. Adjusted EPS from continuing operations was $5.06, compared to $4.90 in 2024, whilst GAAP EPS was $2.07. The Life Sciences segment generated $382 million in fourth quarter revenue with 2% growth, and $1.43 billion for the full year with 2% organic growth. CEO Prahlad Singh said results exceeded expectations and the company is well-positioned following recent portfolio transformation. The company has initiated full year 2026 guidance.